← Back to patent-cliff list
Ropinirole Hydrochloride transdermal (Hisamitsu Pharmaceutical)
Tier C — Watch / tradeRopinirole Hydrochloride transdermal (Hisamitsu Pharmaceutical)
Hisamitsu Pharmaceutical Co., Inc.
Originator
2019
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DRD2
Brand：HARUROPI TAPE
Indications (approved)：Parkinson's disease
Regional status
US
-
EU
-
China
-
Japan
Approved
2019-09-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ropinirole Hydrochloride transdermal (Hisamitsu Pharmaceutical)?
Approved indications include: Parkinson's disease.
When does the Ropinirole Hydrochloride transdermal (Hisamitsu Pharmaceutical) patent expire?
No public expiry year is available for Ropinirole Hydrochloride transdermal (Hisamitsu Pharmaceutical) yet; this page updates once verified.
How do I get a quote for Ropinirole Hydrochloride transdermal (Hisamitsu Pharmaceutical) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29